to defects further downstream in the apoptotic pathway. Van den Berg et al 7 suggested that thermolability of the receptor-ligand complex might be a cause of GC resistance. In refractory and fully resistant murine cell lines non-saturating, low affinity binding of steroid occurred when assayed at 37°C. However, when assayed at room temperature, the intracellular receptors were found to be in a stablebinding, high affinity configuration, masking differences between resistant and sensitive cell lines. This mechanism of resistance would easily escape attention as routine tests are usually performed at room temperature.
In this study we studied GR expression levels and affinities for dexamethasone (DXM) at both room temperature and 37°C in pediatric ALL and AML samples and correlated these data with in vitro GC resistance.
Bone marrow or peripheral blood samples taken for routine diagnostic procedures were obtained from 37 ALL and 10 AML patients at initial diagnosis with informed consent. GR expression and affinity (dissociation constant) for DXM were determined by ligand binding assay as described by Costlow et al, 8 with minor modifications and Scatchard plot analysis of the data. The efflux period necessary for reducing non-specific binding had to be reduced from 10 min at room temperature to 1 min at 37°C due to the rapid ligand-receptor dissocation at 37°C (a 10 min efflux period at 37°C resulted in an unacceptably high 35% loss in specific binding). The dissociation constant (K d value) was expressed in nanomolars (nM). GR levels were expressed as the number of GR molecules per cell and, by including the cellular volume in the equation, as an intracellular concentration in nanomolars (nM). In vitro GC resistance was determined by MTT assay and expressed as the LC 50 value for prednisolone (LC 50 PRD, the prednisolone concentration inducing 50% leukemic cell kill) as previously described.
1 Patients were classified as sensitive (LC 50 PRD р0.1 g/ml), intermediately sensitive (LC 50 PRD Ͻ150 g/ml, but Ͼ0.1 g/ml) or resistant (LC 50 PRD у150 g/ml) to GC-induced cell kill.
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Receptor expression and affinity determined at 23°C and 37°C for the different leukemia subtypes are summarized in Table 1 .
In both ALL and AML receptor concentration (nM) correlated with the number of GR molecules/cell at both incubation temperatures (Rho = 0.7-0.9, P Ͻ 0.02, n = 10 (AML), n = 37 (ALL)), illustrating the relatively small variation in cell size within each leukemia subgroup separately (coefficient of variation of cell volumes was 21% and 27%, respectively, in ALL and AML respectively). Receptor expression was median 15% lower determined at 37°C than at 23°C, but levels correlated strongly with each other (Rho = 0.9, P Ͻ 0.01, n = 47). Since generally similar statistical results were obtained when GR concentration or the number of GR molecules per cell were used, irrespective of the incubation temperature, only results are shown for receptor concentration determined at 37°C unless indicated otherwise.
Receptor affinities determined at 37°C were lower than affinities determined at 23°C (median 2.1 × lower, range 0.86-8.8, P Ͻ 0.001, n = 47). The K d value ranged from 2.8 to 16 nM at 23°C (median 6.4 nM), and from 5.7 to 58 nM at 37°C (median 12 nM). There was no statistically significant correlation between K d values obtained at 23°C and 37°C (Rho = 0.26, P = 0.08, n = 47). We did not find a significant correlation between receptor concentration and dissociation constants determined at 23°C (Rho = 0.13, P = 0.36, n = 47) or at 37°C (Rho = −0.07, P = 0.63, n = 47).
Although AML samples had a higher number of receptors per cell than ALL samples (12720 vs 8790 receptors/cell; P Ͻ 0.05; Table 1), they tended to have a lower receptor concentration (38 vs 62 nM; P = 0.08), reflecting the significantly larger size of AML cells (median 264 vs 474 femtoliter; P Ͻ 0.001). AML and ALL samples had a similar receptor affinity determined at 23°C (median K d 6.6 and 6.0 nM, respectively), but AML samples showed a lower affinity determined at 37°C (median K d 16 nM vs 11 nM in AML and ALL, respectively; P = 0.01).
T-ALL (n = 13) samples had a significantly lower receptor concentration than common/pre-B (n = 22) samples (median 36 vs 70 nM; P Ͻ 0.01). In addition, receptor affinity determined at 37°C was lower in T-ALL (median K d 17 nM) than in common/pre-B ALL (median K d 10 nM; P Ͻ 0.05), but not when determined at 23°C (median K d 6.0 vs 6.1 nM, respectively). The other two ALL samples concerned pro-B ALL cases. 
Leukemia
We observed a weak but statistically significant inverse correlation between GR expression and in vitro GC resistance (Rho = −0.34, P = 0.04, n = 37). Subdivision of the samples into sensitive, intermediately sensitive and resistant revealed that resistant patients had lower GR levels (median 36 nM) than intermediately sensitive (median 72 nM) and sensitive (median 70 nM) patients (P Ͻ 0.05).
In vitro GC resistance did not correlate with the K d values obtained at 23°C in ALL (Rho = 0.026, P = 0.9, n = 37). However, the K d determined at 37°C correlated with the degree of in vitro GC resistance (Rho = 0.35, P = 0.03, n = 37). Median K d values in resistant patients tended to be higher than in sensitive patients (13 nM vs 9.6 nM, P = 0.09; Figure 1) . In order to clarify the relationship between low GR expression or affinity and GC resistance independently from the influence of the T cell immunophenotype (T-ALL samples were more resistant to GCs than common/pre-B ALL: median LC50 PRD 2.1 g/ml vs 0.22 g/ml, respectively; P Ͻ 0.05), we performed the same analyses after exclusion of the 13 T-ALLs. Then, none of the glucocorticoid receptor parameters correlated with GC resistance.
All AML patients were resistant to GC-induced cell kill and correlations with receptor parameters could thus not be studied.
In summary, the ligand GR interaction is temperature dependent. Differences in binding affinities between sensitive and resistant childhood leukemia samples are masked when assayed at room tempera-
Figure 1
Dissociation constants determined at 37°C vs in vitro GC resistance in sensitive (LC 50 PRD р0.1 g/ml), intermediately sensitive (LC 50 PRD Ͻ150 g/ml, but Ͼ0.1 g/ml) and resistant ALL samples (LC 50 PRD у150 g/ml). Medians (sensitive 9.6 nM, intermediate 11 nM and resistant 13 nM) are depicted as horizontal lines. Resistant patients (n = 10) tended to have a lower receptor affinity (higher K d value) than sensitive patients (n = 11; P = 0.09). Common/pre-B samples (n = 22) are depicted as triangles, T-ALL samples (n = 13) as circles and pro-B samples (n = 2) as squares.
Leukemia ture. By assaying at physiological temperatures, however, we were able to demonstrate that, apart from lower GR levels, T-ALL and AML samples (leukemia subgroups relatively resistant to GC-induced cell kill) had receptors with reduced affinity. Follicular lymphoma in advanced stages continues to be a therapeutic challenge with respect to curability. Encouraging results regarding clinical and molecular remission of follicular lymphoma are seen in patients who received combination therapy (R-CHOP) consisting of CHOP (cyclophosphamid, doxorubicin, vincristin, prednisone) and rituximab, the monoclonal CD20 antibody. A less effective therapy may jeopardize a patient's chance for remission, of which, molecular remission seems to be a prerequisite for long disease-free intervals. There are few reports [2] [3] [4] about reactivation of HBV during the treatment of hematological malignancies with rituximab in addition to concomitant or previous chemo-or immunsuppressive therapy (CHOP, fludarabine, prednisone). Confounding factors were present in each case (Table 1 ) leaving an unclear relationship between HBV reactivation and the monoclonal CD20 antibody. In order to elucidate this situation we report our experiences in an HBV-carrying patient who developed severe hepatitis after R-CHOP.
Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge
A 47-year-old man with cervical lymphadenopathy and more than 10% weight loss within the past 6 months was diagnosed with follicular lymphoma, grade 1. Staging procedures showed 60% infiltration of bone marrow (BM), enlarged (2-4 cm) lymph nodes on both sides of the diaphragm, among them at the porta hepatis and splenomegaly
